Pharmaceutical Company Announces Final Clinical Trial Results For Bipolar Treatment

Encouraged by these results, NRx Pharmaceuticals plans to seek accelerated FDA approval for NRX-101 for patients with bipolar depression at risk of akathisia.

Catching the attention of the pharmaceutical industry and investors alike, NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage pharmaceutical company, has announced final clinical trial results showcasing a superior safety profile of NRX-101 over lurasidone in treating suicidal bipolar depression. This announcement, detailed on May 6, 2024, has marked …